History

Background; .biological disease modifiers mainly those targeting tumor necrosis factor (Etanercept), (Infliximab), together with (Adalimumab) are currently an important part of the treatment plan for seropositive poly-articular arthropathy. Since these drugs greatly affect the course of the disease, they alter the treatment of this condition and significantly slow down X-ray progression of the aforementioned condition. Some biologics are designed to precisely suppress tumor necrosis factor (TNF), a key regulator of joint pain and damage. Tumor necrosis factor is a predominant inflammatory interleukin which synchronizes the release of other soluble mediators [1]. Purpose: to assess the changes in P-ANCA an indicator of vascular injury after treatment with the biologic Etanercept (anti-TNFα) in patients with refractory seropositive polyarticular arthropathy. Methods: patients with refractory and classically unrelieved seropositive poly-articular arthropathy received a biological modulator (Etanercept) for 3 months. Participants' sera were collected and examined consecutively for P-ANCA at baseline as well as post-dosing. Statistical analysis was performed using the SPSS 10 .Results: after 3 months, there was a significant decrease in serum anti-lactoferrin level of nearly 97%, and a concomitant increase of anti-lysozyme, with an increase of 551.6%. However, other autoantibodies are elevated, non-importantly.  Conclusion: Etanercept had variable effects on P-ANCA in patients with refractory seropositive poly arthropathy after 3 months of therapy.